56
Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012) http ://www.sccm.org/Documents/SSC- Guidelines.pdf

Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Embed Size (px)

Citation preview

Page 1: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Surviving Sepsis Campaign:

Guidelines for the Management of Severe Sepsis and Septic Shock

(2012)

http://www.sccm.org/Documents/SSC-Guidelines.pdf

Page 2: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Background

Surviving Sepsis Campaign (2002):Barcelona

Original guidelines 2004

Revised 2008

Third edition printed in the February 2013 edition of Critical Care Medicine and Intensive Care Medicine

Page 3: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Aims

Provide guidance for ICU and non-ICU settings

Greatest outcome improvement from non-ICU setting and across the spectrum of acute care

Recommendations aimed to be best practice and not created to represent standard of care

Page 4: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

“The surviving sepsis campaign guidelines committee hopes that over time, particularly through education programs and formal audit

and feedback performance improvement initiatives, the guidelines will influence

bedside healthcare practitoner behaviour that will reduce the burden of sepsis worldwide”

Page 5: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Development of the Guidelines

Committee members

Grading of recommendations: GRADE system

Determines the:Quality of evidence (A-D)

Strength of recommendations as strong (grade 1) or weak (grade 2)

Page 6: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Severe Sepsis and Septic Shock

Sepsis:Systemic, deleterious host response to infection leading to severe sepsis (acute organ dysfunction secondarily to documented or suspected infection)

Septic Shock:Severe sepsis plus hypotension not reversed with fluid resuscitation

Major health-care problems affecting millions of people around the world each year, killing often >1 in 4 people and increasing in incidence

Speech and appropriateness of therapy in the initial hours after severe sepsis develops significantly influences the outcome.

Page 7: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

DefinitionsSepsis:

Presence (probable or documented) of infection together with systemic manifestations of infection

Severe Sepsis:Sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion

Septic Shock:Sepsis-induced hypotension persisting despite adequate fluid resuscitation

Sepsis-induced tissue hypoperfusion = infection-induced hypotension, elevated lactate or oliguria

Page 8: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)
Page 9: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)
Page 10: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

MANAGEMENT OF SEVERE

SEPSIS

Page 11: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Initial Resuscitation

and Infection Issues

Page 12: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

a) Initial Resuscitation –

Early Goal Directed TherapyInitiated as soon as hypoperfusion is recognized

Should not be delayed awaiting ICU admission

Goals during the first 6 hours:CVP 8-12mmHg

MAP >65mmHg

Urine output >0.5 ml/kg/hr

SVCO2 or SVO2 70% or 65% respecitvely

Normalise lactate levels

15.9% absolute reduction in 28-day mortality

Page 13: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

b) Screening for Sepsis and

Performance Improvement

Routine screening of potentially infected seriously ill patients for severe sepsis to allow earlier implementation of therapy

Hospital-based performance improvement efforts in severe sepsis

Page 14: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

c) Diagnosis

Cultures as clinically appropriate prior to anti-microbials if no significant delay (>45min)

At least 2 sets of blood cultures with at least 1 drawn percutaneously and 1 drawn through each vascular access device, unless the device was recently inserted (<48hrs)

Use of 1,3 b-D-glucan assay, mannan and anti-mannan antibody assay in invasive candidiasis

Imaging studies performed promptly to confirm a potential source of infection

Page 15: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

d) Anti-Microbial Therapy

IV antibiotics within 1hr of recognition of septic shock (1b) and severe sepsis without shock (1c) as the goal of therapy

Initial empiric anti-effective therapy of one or more drugs that have activity against all likely pathogens (bacterial +/- fungal or viral) and that penetrate in adequate concentrations into tissues presumed to be the source of sepsis

Failure to initiate appropriate therapy correlates with increased morbidity and mortality in patients with

severe sepsis or septic shock

Page 16: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

d) Anti-Microbial

Therapy cont… Antimicrobial regimen should be reassessed daily for potential de-escalation to prevent the development of resistance, to reduce toxicity and to reduce costs (1b)

Use of low procalcitonin levels or similar biomarkers to assist in the discontinuation of empiric antibiotics in patients who appeared septic, but have no subsequent evidence of infection (2c)

Page 17: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

d) Anti-Microbial

Therapy cont…Antibiotic choice:

Neutropenic: combination empiric therapy

Respiratory failure: combination therapy with extended spectrum beta-lactam and either aminoglycoside or a fluroquinolone (for pseudomonas bacteraemia)

Strep pneumoniae: complex combination of beta-lactam and macrolide

Combination therapy when used empirically should not be administered for longer than 3-5 days. De-escalation to the most appropriate single agent should be performed as soon as susceptibility profile

Duration of therapy typically be 7-10 days if clinically indicated; longer courses in patients who have a slow clinical response, undrainable foci of infection, bacteremia with s.aureus, immunological deficiency (incl neutropenia)

Page 18: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

d) Anti-Microbial

Therapy cont…Use of ant-viral therapy be initiated as early as possible in patients with severe sepsis or septic shock of viral origin (2c)

Anti-microbial agents not be used in patients with severe inflammatory states determined to be of non-infectious cause

Page 19: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

e) Source ControlA specific anatomical diagnosis of infection requiring consideration for emergent source control be sought and diagnosed or excluded as rapidly as possible, and intervention be undertaken for source control within the first 12hr after the diagnosis is made, if feasible (1c)

In Infected peri-pancreatic necrosis, definitive intervention is best delayed until adequate demarcation of viable and non-viable tissues has occurred (2b)

The intervention with the least physiological insult should be used

If intravascular access devices are a possible source they should be removed promptly after other vascular access has been established

Page 20: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

f) Infection Prevention

Selective oral decontamination (SOD) and selective digestive decontamination (SDD) should be introduced and investigated as a method to reduce the incidence of VAP (2b)

Oral chlorhexidine be used as a form of oropharyngeal decontamination to reduce the risk of VAP in patients with severe sepsis (2b)

Page 21: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Haemodynamic Support

And

Adjunctive Therapy

Page 22: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

g) Fluid Therapy of Severe Sepsis

Crystalloids be used as the initial fluid of choice in the resuscitation of severe sepsis and septic shock (1b)

Against the use of HES for fluid resuscitation (1b)

Albumin in the fluid resuscitation of severe sepsis and septic shock when patients require substantial amounts of crystalloids (2c)

Page 23: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

g) Fluid Therapy of Severe

Sepsis cont….

Initial fluid challenge: 30ml/kg

Fluid challenge continued as long as there is haemodynamic improvement either based on dynamic or static variables

Page 24: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

h) VasopressorsVasopressor therapy initially target a MAP of 65mmHg (1c) (Individualise)

Noradrenaline as the first-choice vasopressure (1b)

Adrenaline when an additional agent is needed (2b)

Vasopressin (up to 0.03U/min) can be added to norad with the intent of raising MAP to target or decreasing noradrenaline

Page 25: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

h) Vasopressors

cont…..Low-dose vasopressin not recommended as the single initial vasopressor, and doses higher than 0.03-0.04 U/min should be reserved for salvage therapy

Dopamine as an alternative vasopressor agent to noradrenaline only in highly selected patients (2c)

Low dose dopamine not be used for renal protection (1a)

All patients have an arterial line

Page 26: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

i) Inotropic Therapy

Trial of dobutamine infusion up to 20ug/kg/min in the presence of (1c):

Myocardial dysfunction (elevated cardiac filling pressures and low cardiac output)

Ongoing signs of hypoperfusion, despite adequate intravascular volume and adequate MAP

Against the use of a strategy to increase cardiac index to predetermined supranormal levels (1b)

Page 27: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

j) Corticosteroids

Against using intravenous hydrocortisone as a treatment of adult septic shock in patients if adequate fluid resuscitation and vasopressor therapy are able to restore haemodynamic stability. If this is not achievable, suggest IV hydrocortisone of 200mg/day (2c)

Against the use of ACTH stimulation test to identify the subset of adults who should receive hydrocortisone (2b)

Page 28: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

i) Corticosteroids

cont…..Clinician taper the treated patient from steroid therapy when vasopressors are no longer required (2d)

Recommend corticosteroids not be administered for the treatment of sepsis in the absence of shock (1d)

When low-dose hydrocortisone is given, suggest using continuous infusion rather than repetitive bolus injections (2d)

Page 29: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Supportive therapy of

Severe Sepsis

Page 30: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

k) Blood product administration

Once tissue hypoperfusion has resolved, and in the absence of extenuating circumstances, recommend that red blood cell transfusion occur when the target Hb <7.0 g/dL to target a level of 7.0-9.0 g/dL (1b)

Against using erythropoietin as a specific treatment of anaemia associated with severe sepsis (1b)

FFP not be used to correct clotting abnormalities in the absence of bleeding or planned invasive procedures

Page 31: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

k) Blood product administration

cont….Against the use of Anti-thrombin administration for the treatment of severe sepsis and septic shock (1b)

Platelets be administered prophylactically when counts <10 x109/L in the absence of apparent bleeding, as well as when counts <20 if the patient has a significant risk of bleeding. Higher platelet counts >50 are advised for active bleeding, surgery or invasive procedures (2d)

Page 32: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

l) Immunoglobulins

Against using IV immunoglobulins in adult patients with severe sepsis and septic shock (2b)

m) SeleniumAgainst using IV selenium to treat severe sepsis (2c) (excluding standard use in TPN)

Page 33: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

n) Recombinant Activated Protein C

PROWESS recommendations of its use in the 2008 guidelines

PROWESS-SHOCK 2011:1, 696 pts showing no benefit

Mortality 26.4% cf 24.2% placebo with a relative risk of 1.09

Drug has been withdrawn for the market and is no longer available, so there is no need for an SCC recommendation regarding its use

Page 34: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

o) Mechanical Ventilation in sepsis-

induced ARDSRecommend target a tidal volume of 6ml/kg predicted body weight in patients with sepsis-induced acute respiratory distress syndrome (cf 12ml/kg) (1a)

Recommend plateau pressures be measured in patients with ARDS and that the initial upper limit goal for pressures in a passively inflated lung be <30cmH20 (1b)

9% decrease in all cause mortality

Page 35: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

o) Mechanical ventilation

cont……Recommend PEEP be applied to avoid alveolar collapse at end expiration (atelectotrauma) (1b)

Strategies based on higher rather than lower levels of PEEP for patients with severe sepsis-induced moderate to severe ARDS (2c)

Recruitment maneuvers in sepsis patients with severe refractory hypoxemia due to ARDS (2c)

Prone positioning in severe ARDS in hospitals with experience (2b)

Page 36: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)
Page 37: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)
Page 38: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

o) Mechanical ventilation

cont……Mechanically ventilated sepsis patients be maintained with the head of the bed between 30-45 degrees to limit aspiration risk and to prevent development of VAP (1b)

NIV be used in the minority of sepsis-induced ARDS patients in whom the benefits of NIV have been carefully considered and are thought to outweigh the risks (2b)

Page 39: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

o) Mechanical ventilation

cont……Ventilation weaning protocol be in place and ventilated patients undergo spontaneous breathing regularly to evaluate the ability to discontinue mechanical ventilation when:

Arousable

Haemodynamically stable (off vasopressors)

No new potentially serious conditions

Low ventilatory and end-expiratory pressure requiredment

Low FiO2 requirements (face mask or NP)

If spontaneous breathing trial is successful, extubation should be considered (1a)

Page 40: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

o) Mechanical ventilation

cont……Against the routine use of a pulmonary artery catheter for patients with sepsis-induced ARDS (1a)

Recommend a conservative fluid strategy for patients with established sepsis-induced ARDS who do not have evidence of tissue hypoperfusion (1c)

In the absence of specific indication such as bronchospasm, recommend against the use of b-agonists for treatment of patients with sepsis-induced ARDS (1b)

Page 41: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

p) Sedation, Analgesia,and

Neuromuscular Blockade

Recommend either continuous or intermittent sedation be minimised in mechanically ventilated sepsis patients, targeting specific titration endpoints (1b)

Recommend that NMBAs be avoided if possible in patients without ARDS due to the risk of prolonged blockade following discontinuation. If NMBAs must be maintained, either intermittent bolus as required or continusous infusion with train-of-four monitoring of depth of blockade should be used (1c)

Suggest a short course of NMBA (<48hrs) for patients with early sepsis-induced ARDS and PaO2/FiO2 <150mmHg (2c)

Page 42: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

q) Glucose control

Recommend a protocolised approach to blood glucose management, commencing insulin dosing when two consecutive readings are >180mg/dL (10mmol/L). This approach should target an upper BSL <180mg/dL rather than an upper target of <110mg/dL (7.8mmol/L) (1a)

BSL monitoring every 1-2 hours until glucose values and insulin infusion rates are stable, then every 4hrs thereafter (1c)

BSL obtained from point of care testing be interpreted with caution as may not accurately estimate arterial blood or plasma glucose levels

Page 43: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

r) Renal ReplacementTherapy

Recommend continuous renal replacement therapies and intermittent haemodialysis are equivalent in patients with severe sepsis and acute renal failure because they achieve similar short-term survival rates (2b)

Recommend the use of continuous therapies to facilitate the management of fluid balance in haemodynamically unstable patients (2d)

Page 44: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

s) Bicarbonate therapy

Recommend against the use of sodium bicarbonate for the purpose of improving haemodynamics or reducing vasopressor requirements in patients with hypoperfusion-induced lactic acidaemia with pH>7.15 (2b)

Page 45: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

t) DVT prophylaxis

Recommend daily pharmacoprophylaxis against VTE (1b). Via LMWH. If CL <30ml/min recommend dalteparin or another form of LMWH with low renal metabolism.

Recommend treatment with a combination of pharmacologic therapy and intermittent pneumatic compression devices when possible (2c)

Patients with a contra-indication to heparin use not receive pharmacoprophylaxis (1b) but mechanical treatment (2c) unless contraindicated. When the risk decreases, recommend starting pharmacoprophylaxis (2c)

Page 46: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

u) Stress Ulcer Prophylaxis

Recommend stress ulcer prophylaxis using H2 blocker or proton pump inhibitor be given to those who have bleeding risk factors (1b)

When SUP used, suggest PPI rather and H2 antagonists (2c)

Suggest patients without risk factors should not receive prophylaxis (2b)

Page 47: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

v) NutritionRecommend administering oral or enteral feedings, as tolerated, rather than complete fasting or IV glucose within the first 48hrs after a diagnosis of severe sepsis/septic shock (2c)

Recommend avoiding mandatory full caloric feeding in the first week, but recommend low-dose feeding and advancing only as tolerated (2b)

Recommend IV glucose and enteral nutrition rather than TPN alone or parenteral nutrition in conjunction with enteral feeding in the first 7 days after a diagnosis of severe sepsis/septic shock (2b)

Recomment using nutrition with no specific immunomodulating supplementation (2c)

Page 48: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

w) Setting goals of care

Recommend goals of care and prognosis be discussed with patients and families (1b)

Recommend that goals of care be incorporated into treatment and end-of-life care planning, utilising palliative care principles where appropriate (1b)

Suggest that goals of care be addressed as early as feasible, but no later than within 72hrs of ICU admission (2c)

Page 49: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

SPECIAL CONSIDERATIONs

IN

PAEDIATRICS

Page 50: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Overall mortality from severe sepsis is much lower cf adults (2-10%)

Hospital mortality for severe sepsis in previously healthy children = 2%

Hospital mortality for severe sepsis in chronically ill children = 8%

(USA)

Page 51: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Definitions of sepsis, severe sepsis, septic shock and multi-organ dysfunction/failure syndromes are similar to adult definitions but depend on age-specific heart rate, respiratory rate and WCC.

The SSC guidelines provide recommendations only for term newborns and children in the industrialized resource-rich setting with full access to mechanical ventilation ICUs.

Page 52: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Initial ResuscitationVenous access:

Peripheral IV or intra-osseous access for fluid resuscitation and inotrope infusion when a CVC is not available

Endpoints of Resus:Capillary refill <2 seconds

Normal BP for age

Normal pulses with no differential between peripheral and ventral pulses

Warm extremities

Urine output >1ml/kg/hr

Normal mental status

Recommend following paediatric advanced life support guidelines (figure on handout)

Page 53: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Antibiotics

Empiric drug choice should be changed as epidemic and endemic ecologies dictate

Clindamicin and anti-toxin therapies for toxic shock

Page 54: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Fluid Resuscitation/ Inotropes and vasopressors

Boluses of up to 20ml/kg of crystalloids over 5-10 minutes

Fluids should be titrated to reversing hypotension, increasing urine output and attaining normal capillary refill, peripheral pulses and level of consciousness without inducing hepatomegaly or auscultatory chest changes

Peripheral inotropic support until central access can be attained in children who are not responsive to fluids

Patients with low cardiac output and increased systemic vascular resistance with normal blood pressure be given vasodilator therapies

Page 55: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Adjunctive/Supportive Therapies

ECMO should be used with refractory septic shock

Hydrocortisone therapy in children with fluid-refractory, catecholamine-resistance shock and suspected or proven absolute (classic) adrenal insufficiency

Use of diuretics to reverse fluid overload (or haemofiltration if unsuccessful) to prevent greater than 10% total body weight fluid overload

No recommendation of use of DVT or stress ulcer prophylaxis

Page 56: Surviving Sepsis Campaign: Guidelines for the Management of Severe Sepsis and Septic Shock (2012)

Future Directions

Optimum treatment of severe sepsis and septic shock is a dynamic and evolving process

Additional evidence has appeared since the 2008 guidelines

New interventions will be proven and established interventions may need modification